

Academia continues rapid adoption of DiscoveryGate® platform

“DiscoveryGate enables chemistry researchers, staff and students alike, to access a very useful suite of chemistry databases and links to other scientific information. The ability to access such comprehensive information anywhere on campus will enable researchers to save time locating relevant materials and accelerate decision making.”

David Clay *Deputy Head of Academic Liaison and Finance* University of Liverpool Library

institutions such as Harvard University, Stanford University, University of Chicago, Max Planck Institute, University of Auckland, Hong Kong University, University of Liverpool, Tokushima Bunri University, University of Barcelona and the Vienna University of Technology.

“DiscoveryGate enables chemistry researchers, staff and students alike, to access a very useful suite of chemistry databases and links to other scientific information,” says David Clay, Deputy Head of Academic Liaison and Finance, University of Liverpool Library. “The ability to access such comprehensive information anywhere on campus will enable researchers to save time locating relevant materials and accelerate decision making.”

“The rapid adoption of DiscoveryGate by pre-eminent, global research institutions is enabling more researchers to gain insight from the complete suite of databases in the DiscoveryGate academic package,” says Tim Hctor, Product Manager for Market Strategy, Academic & Government (A&G) and Emerging Markets.

University of Wisconsin supports DiscoveryGate® for academic consortia

The University of Wisconsin is providing full technical support to all members of the North American MINERVA consortium that license either the full DiscoveryGate® content platform or the Beilstein and/or Gmelin databases using the DiscoveryGate platform. The University of Wisconsin currently hosts the MINERVA and MENTOR programs that provide students, faculty and researchers at over 100 North American universities with unlimited access to their respective licensed databases, including CrossFire Beilstein, CrossFire Gmelin and MDL® chemical sourcing, bioactivity and synthetic methodology databases.

“The University of Wisconsin is pleased to expand our role with the academic, scientific research and library communities by supporting DiscoveryGate from Elsevier MDL,” said Nolan Pope, Associate Director for Technology, General Library System, UW-Madison. “Extending technical and user support to the DiscoveryGate platform enables the growing number of North American universities to benefit from this important chemistry and life science resource.”

The University of Cambridge, Ecole Polytechnique Federale de Lausanne, Yale University and Centre d'Etudes de Saclay (part of the French government-funded Commissariat à l'Energie Atomique) are among the many academic institutions that have recently licensed the DiscoveryGate academic package, joining other prestigious research

DiscoveryGate® | MDL® Database Browser

queries results reports

copy to report export records export selected citations page setup print save refine query lists help logout MDL® Compound Index Version

Return to Search Results View selected records in another database Record # 1 Total Records: 1

Also found in: ACD CCR CIRX CMC DWPI MDDR MetaCore MetaDrug Metabolite OHS MSDS Patent Chemistry PharmaPendium PubChem SCD Toxicity xPharm

Select all citations / Deselect all citations

Terrestrial degree of freedom 3
 clogP (Syracuse Res. Center) 3.47
 Molecular Formula C17 H14 F3 N3 O2 S
 Mol. WeightLargest Fragment 381.377
 Proton Acceptors (O+N) 5
 Molecular Weight 381.377
 Total Polar Surface Area 86.36
 Rule of Five 0
 Proton Donors 1

DiscoveryGate® xPharm®

Home Contents Search Agents Targets Disorders Principles

Quick Search within All xPharm Search Tips About | Logout

Celecoxib
 Version 2
 Sarah Miles
 Click here to cite this article.

Introduction

Celecoxib, a selective inhibitor of cyclooxygenase-2, is a non-steroidal antiinflammatory agent. An antiinflammatory, analgesic, and antipyretic drug, celecoxib is used for the treatment of a number of inflammatory diseases, such as arthritis (rheumatoid and osteoarthritis) and familial adenomatous polyposis. There are data suggesting that celecoxib may possess anticancer properties. As a selective inhibitor of cyclooxygenase-2, celecoxib appears to display fewer side effects than nonselective nonsteroidal antiinflammatory agents such as aspirin.

Nomenclature

Name of the Clinical Form	Celebres; Celcox; Celebra; Solexa
Related Names	Celecoxib; 4-[(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide]; Celebrex; SC-58635; 4-[(5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide]; celebra; celebrex; 4 [5 (4 methylphenyl) 3 trifluoromethyl 1h pyrazol 1y]benzenesulfonamide; sc 58635; ym 177; 4 [5 (4 methylphenyl) 3 trifluoromethyl 1h pyrazol 1 y]benzenesulfonamide; onsenai; sc58635; ym177
Chemical Names	4-[(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide]
CAS Number	169590-42-5

DiscoveryGate provides “Also found in” links at the top of each record, offering immediate connections to relevant information on the same compound in other data sources, in this example Celecoxib, a known COX-2 inhibitor.

“DiscoveryGate serves tens of thousands of eligible users at more than 400 commercial, academic and government institutions worldwide,” says Hoctor. “With over 500 institutions conducting full or individual evaluations this year, we have seen close to 80% growth in the A&G sector for licensing the full DiscoveryGate package.”

DiscoveryGate for academia features a campus-wide access model. When an institution licenses DiscoveryGate, any number of eligible researchers at the institution may use the service—access is not limited to a few people at a time.

DiscoveryGate is supported on both the Microsoft Windows® and Apple® Macintosh® OS X platforms. Because DiscoveryGate is widely deployed in the commercial research environment, hands-on experience with the platform in the university setting prepares students for success in today’s highly competitive job market.

DiscoveryGate’s unique integration and linking of content enables researchers to compare information and results that are not available through other systems. With the indexing of important new data sources this year (e.g., PharmaPendium™ drug safety resource, PubChem® database, GeneGo systems biology/pathway analysis platform, etc.), DiscoveryGate now provides detailed scientific information on more than 22 million chemical compounds, 11 million reactions and 500 million observed chemical facts, including synthesis, bioactivity, metabolism, toxicology, physical property, chemical sourcing, pharmacology and patent data—all from a single query.

Researchers can access 17 databases including the Beilstein and Gmelin databases (which are also available on the CrossFire system from MDL Information Systems GmbH), MDL® Available Chemicals Directory, MDL® Drug Data Report, MDL®

“The ability to know when information is available in other systems and link directly to it without conducting an extra search is a significant advantage in terms of time savings and locating relevant materials...”

Dr. Ulrich Jordis *Institute of Applied Synthetic Chemistry* Vienna University of Technology

Toxicity Database and authoritative reference works on synthetic methodology. Researchers can also link to over 20,000 journal titles (with additional licenses required to access certain third-party content).

Research universities are not the only groups electing to license content on the DiscoveryGate platform. The European Patent Office has licensed the MDL® Patent Chemistry Database for use in evaluating patent applications. King Fahad National Guard Hospital in Saudi Arabia recently licensed the xPharm® reference database for pharmacology. The National Centre of Oncological Research in Spain has licensed the full content package on DiscoveryGate, joining other world-class organizations such as City of Hope Medical Center and St. Jude Children’s Hospital by providing full access to chemistry, bioactivity, toxicity and pharmacology data in a single integrated platform available to all of their users.

“The ability to know when information is available in other systems and link directly to it without conducting an extra search is a significant advantage in terms of time savings and locating relevant materials,” says Dr. Ulrich Jordis of the Institute of Applied Synthetic Chemistry at the Vienna University of Technology.

To learn more about how DiscoveryGate helps academic researchers find the information they need, visit

www.discoverygate.com, contact your Elsevier MDL Account Manager or request information at www.mdl.com.

DiscoveryGate Auto-Update feature provides effortless, timely updates

The DiscoveryGate Auto-Update feature, enabled by default¹, provides effortless and timely updates to MDL® Database Browser, the search and display application for hosted databases on the DiscoveryGate content platform.

When updates are made to MDL Database Browser to accommodate new content or to enhance usability and performance, it is necessary to update certain Java files (.jar) in the DiscoveryGate client.

The Auto-Update feature provides a simple and convenient update alternative by eliminating the need to download and run the updated DiscoveryGate client installer.

Auto-Update automatically compares and updates (if required) the Java files used by the DiscoveryGate client, on login to the DiscoveryGate platform. During this process, no changes are made to the customer machine’s registry and no executable files are installed.

Elsevier MDL recognizes the critical importance of the security and integrity of information that transits the DiscoveryGate system and manages DiscoveryGate data transmission using industry-standard security protocols. A White Paper detailing the security, privacy and confidentiality policies pertaining to the DiscoveryGate platform is available for review.

www.mdl.com/products/pdfs/discoverygate_security.pdf

¹DiscoveryGate administrators can disable Auto-Update for their entire site. Auto-Update will not update files if system settings have been enabled to prevent automatic file updates.

See more information on DiscoveryGate including this article as a reprint (PDF). www.mdl.com

See interactive DiscoveryGate videos. www.mdl.com/videos

Read a review article about xPharm® reprinted from the Journal of Electronic Resources in Medical Libraries, courtesy of The Haworth Press, Inc. www.mdl.com/products/pdfs/xpharm.pdf

Sign-up for a 30-day trial of DiscoveryGate (no fee, no obligation to buy, subject to acceptance of the applicable DiscoveryGate Evaluation license). www.discoverygate.com

More information



Elsevier MDL
2440 Camino Ramon,
Suite 300
San Ramon, CA 94583
Tel: +1 (925) 543-5400
Fax: +1 (925) 543-5401
www.mdl.com

MDL, Available Chemicals Directory, DiscoveryGate and PharmaPendium are registered trademarks or trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States and/or other countries. CrossFire is Copyright © 1995-2007 and a registered trademark of MDL Information Systems GmbH in Germany. Beilstein Database: Copyright © 1988-2007. Beilstein-Institut zur Förderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH. Gmelin Database is Copyright © 2000-2007. Gesellschaft Deutscher Chemiker, licensed to MDL Information Systems GmbH, used herein under permission and Copyright © 1988-1999, Gmelin Institut für Anorganische Chemie und Grenzgebiete der Max Planck-Gesellschaft zur Förderung der Wissenschaften. Apple and Mac OS X are trademarks or registered trademarks of Apple, Inc. in the United States and other countries; used herein referentially and by permission; use implies no affiliation with or endorsement by Apple of Elsevier MDL or its products or services. Microsoft is a registered trademark of the Microsoft Corporation in the United States and other countries. Prous Science is a registered trademark in the United States of Prous Science, S.A. MDL® Drug Data Report database contains material belonging to Prous Science, S.A., Copyright 1989-2007. All rights reserved. Use of all such material is governed by your Elsevier MDL license agreement. xPharm is a registered trademark of Elsevier, Inc. in the United States and other countries. All other product and company names mentioned herein may be trademarks or registered trademarks of their respective holders. © Copyright 2007 Elsevier MDL. All rights reserved.